Login to Your Account

Iressa Granted FDA Approval; EGFR Research Marching On

By Randall Osborne

Tuesday, May 6, 2003
Almost eight months after a positive FDA panel review, AstraZeneca plc won accelerated approval Monday for Iressa (gefitinib), its epidermal growth factor receptor tyrosine kinase inhibitor pill for advanced non-small-cell lung cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription